Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315505 | 0.83 | CCR2 (0.46) | CCR2TRPV1PDE10A | |
| SCHEMBL3313172 | 0.77 | PARP10 (0.46) | CCR2 | |
| SCHEMBL20757938 | 0.77 | KDM4E (0.47) | USP30HDAC1HDAC2KDM4EBRD3 | |
| SCHEMBL3313206 | 0.76 | DDB1 (0.43) | USP30HPGDSHDAC1HDAC2 | |
| SCHEMBL20757256 | 0.75 | KDM4E (0.48) | USP30HDAC1HDAC2KDM4EBRD3 | |
| SCHEMBL3317404 | 0.74 | ALDH1A1 (0.40) | CCR2TRPV1PDE10A | |
| SCHEMBL20757935 | 0.73 | KDM4E (0.46) | USP30HDAC1HDAC2KDM4EBRD3 | |
| SCHEMBL22059962 | 0.73 | KDM4E (0.46) | USP30HDAC1HDAC2KDM4E | |
| SCHEMBL30700671 | 0.73 | KDM4E (0.46) | USP30HDAC1HDAC2KDM4E | |
| SCHEMBL9900230 | 0.72 | HDAC1 (0.48) | USP30HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-1933830-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | CCR2 734/4885USP30 4653/4885HPGDS 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.